Influenza immunization in the light of global trends: advances and prospects.
On 07 October 2019, Moscow hosted a special panel session of the National Assembly «Protected Generation» on improvements of the National Immunization Schedule and vaccine label expansion. The Assembly was a unique venue that united representatives of scientific and medical communities, federal and regional health and state authorities.
The Assembly included a symposium titled «Influenza immunization in the light of global trends: advances and prospects». The scientific panel session was moderated by Acad. Leila S. Namazova-Baranova, Chairwoman of the Executive Committee of the Union of Pediatricians of Russia. The speakers were lead immunization and influenza prevention experts. Each of them presented his/her opinion on the current and future vaccine manufacturing aspects worldwide and population immunization opportunities. All speakers emphasized that adjuvanted vaccines were currently one of the most promising trends.
According to the expert, efficacy and safety profiles of Azoximer bromide, an adjuvant that has been for many years used in Grippol plus influenza vaccine, have been thoroughly studied. The study data suggests that an Azoximer bromide adjuvanted vaccine is as efficacious with a lower antigen dose as a non-adjuvanted vaccine containing a higher antigen dose, including in the risk groups, and at the same time is characterized by a lower reactogenicity. By way of summing up, the speaker said that one of the main vaccine development trends would engage adjuvants.
Mikhail P. Kostinov, Head of Immunization and Immunotherapy Laboratory at I.I. Mechnikov Research Institute of Vaccines and Sera, presented a recent study on the dendritic cell role in the formation of influenza immunity. The expert noted that adjuvants promoted the formation of specific antibodies in a shorter period as well as had an impact on their quality, i.e. high-affinity antibodies were produced that were responsible for intensive neutralization of the influenza viruses invading the body.
Ivan V. Konovalov, senior lecturer of the Infectious Children’s Disease Chair at N.I. Pirogov Russian National Research Medical University under the MoH, emphasized that adjuvanted influenza vaccines containing Azoximer bromide and reduced flu virus antigen doses, were efficacious and safe in all risk groups. In follows from the studies evaluating preventative efficacy of immunization that Grippol plus decreases influenza and ARVI incidence rates in the immunized children in pre-school childcare setting 8.3x, and that of school children — 6.7x as compared to those not immunized. According to I.V. Konovalov, an adjuvanted influenza vaccine decreases exacerbation rates in patients with chronic cardiovascular and pulmonary diseases: COPD — 2.5x, bronchial asthma — 1.9x, cardiovascular diseases — 1.6x, as well as decreases antibiotics use 3.6x.
More than 700 experts took part in the panel session. Most of them used an ad hoc online platform that provided for live streaming of the events and interaction with the speakers.